At a glance
ClinicalIndex Comparison RecordN/AUnknown· 1 target
Drug / intervention
Soy foodsother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Meta-analysis of 46 Studies Identified by the FDA on the Effect of Soy Protein on Lipid Markers (LDL-Cholesterol [LDL-C] and Total Cholesterol [TC]) as Surrogates of Cardiovascular Disease
In Brief
An observational study evaluating Soy foods for Cardiovascular Diseases. Targeting 1 participant across 2 sites.
Detailed Summary
The FDA have revised the data on soy and concluded that a heart health claim is no longer justified based on more recent studies. They are allowing and established panel for public input. The selected studies have not been meta-analyzed, therefore we will conduct a meta-analysis of the 46 FDA selected studies to assess the effect of soy protein on surrogate markers of cardiovascular disease (LDL-C and TC).
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsCardiovascular Diseases
CountriesCanada
Collaborators--
Timeline
N/AUnknownOverdue
201820192020202120222023202420252026
Enrollment StartMar 2018
First PostedMar 2018
Primary CompletionApr 2018
Study CompletionMay 2018
TodayJul 2026
First PostedMar 16, 2018
Enrollment StartMar 7, 2018
Primary CompletionApr 19, 2018
Study CompletionMay 31, 2018
TodayJul 1, 2026
Enrollment to primary: 1 monthPosted 8.3 years ago
Interventions
Soy foodsother
Isolated soy protein, soy protein, soybean products, soy milk